essential-medical

Essential Medical, Inc., a privately held medical device company addressing the rapidly growing large bore vascular closure market, announced today that it has completed a Series B financing of $14.9M.

The round was led by Amzak Health along with original Series A investors including DSM Venturing, the venture investment arm of Royal DSM.

Greg Walters, President and CEO of the company, stated, “We are thrilled that Amzak Health has the confidence in the novel Essential Medical technology and our team to lead this round of financing along with our original investors. The Amzak group will also provide additional expertise and experience to our board of directors as our company transitions to commercialization in Europe and the initiation of the US clinical trial for our MANTA product.”

MANTA is a novel CE Marked vascular closure device designed to close punctures ranging from 10F to 24F at femoral arterial access sites after cardiac catheterization procedures such as transcatheter aortic valve replacement (TAVR), endovascular treatment of abdominal aortic aneurysms (AAA/EVAR), ventricular assist (VAD), and balloon aortic valvuloplasty (BAV).

Read the full article here.